SCHEMBL15211575

SCHEMBL15211575

O=C(O)c1coc2cc(OCc3ccc(Cl)cc3Cl)ccc12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 2/20 0.58
POLB P06746 2/20 0.57
SLC26A4 O43511 2/20 0.57
NR4A1 P22736 1/20 0.55
NR4A3 Q92570 1/20 0.55
FABP3 P05413 1/20 0.50
FABP4 P15090 1/20 0.50
FABP5 Q01469 1/20 0.50
PPARD Q03181 2/20 0.46
PPARA Q07869 1/20 0.46
S1PR1 P21453 1/20 0.46
LTK P29376 1/20 0.46
TAOK1 Q7L7X3 1/20 0.46
S1PR5 Q9H228 1/20 0.46
MRGPRX4 Q96LA9 1/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
ALDH1A1 P00352 1/20 0.44
MAPT P10636 1/20 0.44
NCOA1 Q15788 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15211684 0.88 POLB (0.52) NR4A2POLBSLC26A4NR4A1NR4A3
SCHEMBL15211617 0.85 PPARD (0.63) NR4A2POLBSLC26A4NR4A1NR4A3
SCHEMBL17431378 0.81 POLB (0.53) NR4A2POLBSLC26A4NR4A1NR4A3
SCHEMBL15211619 0.81 POLB (0.52) NR4A2POLBSLC26A4NR4A1NR4A3
SCHEMBL15211552 0.80 POLB (0.51) NR4A2POLBSLC26A4NR4A1NR4A3
SCHEMBL15211427 0.79 POLB (0.48) NR4A2POLBSLC26A4NR4A1NR4A3
SCHEMBL17431396 0.78 POLB (0.47) NR4A2POLBSLC26A4NR4A1NR4A3
SCHEMBL17431469 0.78 MTNR1A (0.57) NR4A2POLBSLC26A4PPARDPPARA
SCHEMBL15211481 0.78 PPARD (0.48) NR4A2POLBSLC26A4NR4A1NR4A3
SCHEMBL15211478 0.78 PPARD (0.48) NR4A2POLBSLC26A4NR4A1NR4A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2838891-B1 AROMATIC RING COMPOUND AS GHRELIN O-ACYLTRANSFERASE INHIBITOR TAKEDA PHARMACEUTICALS CO (JP) 2017-08-02 EP disclosed
EP-2838891-B1 AROMATIC RING COMPOUND AS GHRELIN O-ACYLTRANSFERASE INHIBITOR TAKEDA PHARMACEUTICALS CO (JP) 2017-08-02 EP disclosed
US-9238639-B2 Aromatic ring compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-19 US disclosed
US-9238639-B2 Aromatic ring compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-19 US disclosed
US-9238639-B2 Aromatic ring compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-19 US disclosed
US-20150119407-A1 SUBSTITUTED XANTHINE DERIVATIVES SUN PHARMACEUTICAL INDUSTRIES, INC. 2015-04-30 US disclosed
EP-2838891-A1 AROMATIC RING COMPOUND Takeda Pharmaceutical Company Limited (JP) 2015-02-25 EP disclosed
WO-2013125732-A1 AROMATIC RING COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150119407-A1 SUBSTITUTED XANTHINE DERIVATIVES XDH, SLC10A1, HPRT1 NR4A2 972/4885POLB 3450/4885SLC26A4 77/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.